Aspira Pathlab Share Price Today | Stock Price & Aspira Pathlab Share Screener
As of October 5, 2026, the live Aspira Pathlab share price (BSE: ASPIRA) is ₹125.10, down 4.69% from the previous close, with shares trading between ₹125.10 and ₹131.25 in today's trading session, and a 52-week range of ₹54.00–₹143.34. Check ASPIRA price range for the annual price range and momentum. Use the Aspira Pathlab stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Aspira Pathlab opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Aspira Pathlab Share Price Chart
Track the current stock price of Aspira Pathlab with an interactive chart. Analyse ASPIRA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Aspira Pathlab stock quote in one place.
The quote of ₹125.10 sits between the 52-week low of ₹54.00 and the 52-week high of ₹143.34, and the latest session moved -4.69% from the previous close.
Aspira Pathlab Company Profile - Fundamental Screener
Screen Aspira Pathlab company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ASPIRA shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare Services sector and the Healthcare Service Provider industry, and it trades under ISIN INE500C01017.
Company Details
Classification
Identifiers and Leadership
Aspira Pathlab Balance Sheet Screener
Screen ASPIRA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2025, total assets were ₹18, up from ₹15 in 2024.
Latest statistics put total assets at ₹18 and shareholder funds at ₹12, with a leverage ratio of 0.15.
| Item | 2025 | 2024 |
|---|---|---|
Assets |
||
| Total Assets | 18 | 15 |
| Current Assets | 5 | 4 |
| Fixed Assets | 7 | 7 |
Liabilities |
||
| Total Liabilities | 0 | 0 |
| Current Liabilities | 3 | 3 |
| Non-Current Liabilities | 0 | 0 |
Shareholders' Equity |
||
| Total Equity | 12 | 10 |
| Share Capital | 10 | 10 |
| Reserves & Surplus | -3 | -5 |
Aspira Pathlab Income Statement Screener - Profit & Revenue Analysis
Screen Aspira Pathlab income statement and profit fundamentals. Analyze ASPIRA quarterly results. Aspira Pathlab reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2025-Jun, revenue was ₹5 and net profit was ₹0, equal to earnings per unit of ₹0.41, at an operating margin of 13%.
In that period expenses were ₹5, interest cost ₹0 and tax ₹0. The next period listed, 2025-Mar, shows revenue of ₹6 and net profit of ₹1.
| Item | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Jun |
|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||
| Revenue | 5 | 6 | 6 | 6 | 5 | 4 | 3 |
| Expenses | 5 | 5 | 5 | 5 | 4 | 4 | 3 |
Operating Costs and Margins | |||||||
| EBITDA | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Operating Profit % | 13.00% | 16.00% | 11.00% | 21.00% | 6.00% | -5.00% | -17.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||
| Profit Before Tax | 0 | 1 | 0 | 1 | 0 | -1 | -1 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 1 | 0 | 1 | 0 | -1 | -1 |
| EPS | 0.41 | 0.66 | 0.30 | 0.96 | 0.05 | -0.49 | -0.70 |
Aspira Pathlab Cash Flow Screener - Liquidity Fundamentals
Screen ASPIRA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹2, and net cash flow was an inflow of ₹1.
Over the same period, investing activities provided ₹0 and financing activities used ₹1.
| Item | 2025-March | 2024-March |
|---|---|---|
Cash from Operations and Investing | ||
| Operating Activities | 2 | 1 |
| Investing Activities | 0 | 0 |
Financing and Net Cash | ||
| Financing Activities | -1 | -1 |
| Net Cash Flow | 1 | 0 |
Aspira Pathlab Shareholding Pattern Screener
See Aspira Pathlab shareholding pattern with promoter, FII, and DII holdings. Check Aspira Pathlab promoter holding and ownership changes for ASPIRA on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Jun, promoters held 46.58%, foreign institutions 0.00%, domestic institutions 0.00% and the public 40.70%, spread across 1,620 shareholders.
The shareholder count was 1,620 in 2026-Jun, compared with 1,769 in 2026-Mar.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 46.58% | 18.39% | 18.39% | 18.39% | 18.39% | 18.39% | 18.55% | 18.55% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 40.70% | 60.06% | 60.07% | 60.16% | 60.28% | 60.46% | 60.28% | 61.26% |
| Other Holding | 12.72% | 21.55% | 21.54% | 21.45% | 21.33% | 21.15% | 21.18% | 20.19% |
| Shareholder Count | 1,620 | 1,769 | 1,784 | 1,755 | 1,770 | 1,741 | 1,593 | 1,706 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Aspira Pathlab. Aspira Pathlab dividend yield can be compared with peers and other stocks in the market.
Aspira Pathlab Stock Index Membership - Nifty & Sensex
See which indices include Aspira Pathlab stock. Check ASPIRA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Aspira Pathlab Market Events Screener - Corporate Actions
Get Aspira Pathlab corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Aspira Pathlab stock events that may affect ASPIRA share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Annual General Meeting dated September 25, 2026, with a record date of September 25, 2026.
It is followed by Quarterly Result Announcement dated August 12, 2026 and Quarterly Result Announcement dated May 23, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-25 | 2026-09-25 | Annual General Meeting | NA | 42.04% |
| 2026-08-12 | 2026-08-12 | Quarterly Result Announcement | NA | -7.64% |
| 2026-05-23 | 2026-05-23 | Quarterly Result Announcement | NA | 24.57% |
| 2026-02-10 | 2026-02-10 | Quarterly Result Announcement | NA | 13.68% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -0.33% |
| 2025-09-26 | 2025-09-26 | Annual General Meeting | NA | -1.79% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -6.20% |
| 2025-05-16 | 2025-05-16 | Quarterly Result Announcement | NA | -12.33% |
| 2025-02-07 | 2025-02-07 | Quarterly Result Announcement | NA | -9.00% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 23.16% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | 27.67% |
| 2016-11-16 | 2016-11-16 | Change Of Name | NA | - |
Aspira Pathlab Competitors Screener - Peer Stocks Comparison
Screen ASPIRA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare Services sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Dr. Lal Path Labs | 32,696 | 59.65 | 2,864 | 12.11% | 510 | 58.55 |
| Vijaya Diagnostic Centre | 15,177 | 82.40 | 835 | 19.34% | 173 | 47.24 |
| Metropolis Healthcare | 11,658 | 58.51 | 1,671 | 24.15% | 191 | 40.73 |
| Thyrocare Technologies | 8,708 | 49.67 | 846 | 20.48% | 163 | 40.51 |
| Nephrocare Health Services | 6,657 | 79.69 | 1,023 | 32.93% | 77 | 35.51 |
| Suraksha Diagnostic | 1,849 | 51.63 | 314 | 22.55% | 31 | 65.77 |
| Krsnaa Diagnostics | 1,796 | 17.83 | 816 | 9.90% | 101 | 50.95 |
| 3B BlackBio DX | 1,393 | 24.11 | 142 | 27.17% | 61 | 68.55 |
| One Global Service Provider | 1,044 | 14.38 | 499 | 237.48% | 70 | 45.89 |
| Health X Platform | 907 | -34.21 | 1,319 | 12.68% | -3 | 37.93 |
Aspira Pathlab Company Announcements - News & Reports Screener
Screen ASPIRA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 5, 2026.
The next most recent announcements are dated October 3, 2026 and October 3, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-05 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-10-03 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-03 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-30 | Closure of Trading Window | - |
| 2026-09-16 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-12 | Announcement Under Regulation 30_Constitution Of Right Issue Committee | - |
| 2026-09-12 | Announcement under Regulation 30 (LODR)-Raising of Funds | - |
| 2026-09-12 | Board Meeting Outcome for Outcome Of Board Meeting Held On 12Th September 2026 | - |
| 2026-09-12 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-07 | Board Meeting Intimation for To Consider Approve The Proposal For Raising Funds Through The Issuance Of Equity Shares Warrants Convertible Into Equity Shares Or Other Permitted Instruments By Way Of Preferential Issue Private Placement Rights Issue Or Any | - |
| 2026-09-05 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-03 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-09-01 | Letters Dispatched To Non-Email Shareholders | - |
| 2026-09-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-31 | Reg. 34 (1) Annual Report. | - |
| 2026-08-31 | Notice Convening 53Rd Annual General Meeting To Be Held On Friday September 25 2026 At 02.00 P.M Through Video Conferencing Mode. | - |
| 2026-08-31 | Intimation Of Book Closure Date Notice Of The 53Rd Annual General Meeting And E-Voting Date | - |
| 2026-08-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-28 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹125.10, within a 52-week range of ₹54.00 to ₹143.34. The P/E ratio is 58.59 and the P/B ratio is 19.42, with earnings per unit of ₹1.97. Market capitalisation stands at ₹147.52 Cr. The company operates in the Healthcare Services sector, in the Healthcare Service Provider industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 6, 2026. This page covers 2 balance sheet periods, 7 income statement periods, 2 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.